Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug ...

The funding will enable Stalicla to advance its autism-focused drug candidates, support asset partnering, prepare for its Series C financing, and cover general corporate activities. This investment in ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a ...

Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in co ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland - June 30, 2025 - Addex Therapeutics(SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel ...

"A safe and effective therapeutic to address the epidemic of CNS metastases and specifically leptomeningeal ... Research Institute of Texas (CPRIT), the second largest public funding source for cancer ...

With the new SBIR funding, Quiver will further augment their existing ASO drug development capabilities by applying their platform to better prediction of ASO CNS toxicity using a combination of ...

For decades, international researchers have received a small slice of the National Institutes of Health budget. In 2024, out ...

Researchers in Democratic congressional districts stand to have $2.1 billion in NIH grants reinstated, compared to $62 ...

Canceled grants and slashed budgets are disproportionately affecting junior health researchers, dealing a major blow to the ...

Drastic cuts to NIH will halt brain research on the cusp of transformational treatments. These setbacks could derail future cures in ways that we may not be able to recover from for decades.